Engineering FKBP-Based Destabilizing Domains to Build Sophisticated Protein
Regulation Systems by An, Wenlin et al.
RESEARCH ARTICLE
Engineering FKBP-Based Destabilizing
Domains to Build Sophisticated Protein
Regulation Systems
Wenlin An1,2, Rachel E. Jackson1, Paul Hunter1, Stefanie Gögel2, Michiel van Diepen1,
Karen Liu3, Martin P. Meyer1, Britta J. Eickholt1,2*
1 MRCCentre for Developmental Neurobiology, King’s College London, London, SE1 1UL, United Kingdom,
2 Charité - Universitätsmedizin Berlin, Cluster of Excellence NeuroCure and Institute of Biochemistry, Berlin,




Targeting protein stability with small molecules has emerged as an effective tool to control
protein abundance in a fast, scalable and reversible manner. The technique involves tag-
ging a protein of interest (POI) with a destabilizing domain (DD) specifically controlled by a
small molecule. The successful construction of such fusion proteins may, however, be lim-
ited by functional interference of the DD epitope with electrostatic interactions required for
full biological function of proteins. Another drawback of this approach is the remaining
endogenous protein. Here, we combined the Cre-LoxP system with an advanced DD and
generated a protein regulation system in which the loss of an endogenous protein, in our
case the tumor suppressor PTEN, can be coupled directly with a conditionally fine-tunable
DD-PTEN. This new system will consolidate and extend the use of DD-technology to control
protein function precisely in living cells and animal models.
Introduction
Phosphatase and tensin homolog located on chromosome 10 (PTEN) is one of the most com-
monly mutated or deleted tumor suppressors in human cancer that is also causally linked to
autism spectrum disorder [1,2]. Changes in PTEN expression level leads to aberrant cell cycle
progression as well as to alterations in cell migration [3,4], amongst other cellular responses.
However, it is still a considerable challenge to ascertain the minimum alteration in PTEN level
or activity that can cause the onset of tumor formation [5] or neurological changes [6], or
whether disease states can be ameliorated by reinstalling PTEN expression. Our ability to
address questions of this nature are currently limited by the lack of experimental systems that
allow the targeted and reversible regulation of PTEN [7]. We set out to exploit FKBP DD-tech-
nology to control PTEN protein function in a rapid, reversible and tunable manner. FKBP is a
12kDa FK506 binding protein, which is broadly expressed in various tissues and functions as a
protein chaperone for newly synthesized polypeptides [8]. An engineered human FKBP has
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been developed that is able to bind a small synthetic ligand, Shld1, with 1000-fold selectivity
over wild-type FKBP due to an amino acid (aa) substitution at F36 (F36V) [9]. A further aa
substitution at L106 (L106P) causes FKBP to degrade rapidly in the absence of Shld1 [10].
Here, we further modified FKBPF36V/L106P by neutralizing highly charged surface amino acid
residues, thereby eliminating the ability of the DD to interfere with electrostatic interactions
required for full biological function of proteins. In case of PTEN, we demonstrate that
FKBPF36V/L106P/E31S/D32S-PTEN permits rapid, reversible and tunable regulation of PTEN func-
tion in cellular and zebrafish models. We further eliminated a potential Cre pseudo-cleavage
site within the FKBP gene sequence to render the system compatible with the Cre-LoxP sys-
tem. In conjunction, the two components will facilitate the study into protein network func-
tion, as FKBP-tagged proteins and conditional mouse alleles can be combined as required by
the experimental set-ups.
Material and Methods
All animal procedures were approved by the local Animal Welfare and Ethics Review Body
(King’s College London) and were carried out in accordance with the Animals (Scientific Pro-
cedures) Act 1986, under license from the United Kingdom Home Office.
Materials and cloning
Rabbit anti-PTEN (138G6), anti-AKT and anti-pAKT (Ser473) antibodies were from Cell Sig-
naling Technology; the mouse anti-PTEN (A2B1) from Santa Cruz Biotechnology; mouse
monoclonal anti GAPDH from Abcam. Phalloidin-Alexa fluorophores conjugates and anti-
rabbit secondary antibody were obtained from Molecular Probes. pCDNA3+ (Invitrogen) and
pCAG vector (a gift from Dr. Kobayashi Mime) were modified by adding HindIII and NotI
sites. The FKBP-PTEN cassettes for linker optimization or surface engineering were cloned
into pcDNA3+ or pCAG byHindIII and NotI sites. The construct pCAG-FKPTEN was gener-
ated by cloning a Neomycin resistance gene cassette and the FKBP-PTEN open reading
frame into the pCAG vector. The CTV vector (Addgene) was used to create constructs M3Lcta
and M3Lttg by inserting FKBP-PTEN gene at the AscI site.
Cell culture
PTEN null U87MG cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) media
containing 10% FCS and 1% penicillin/streptomycin. The U87MG cell line stably expressing
FKBP-PTEN was generated by G418 selection (500 μg/ml) and maintained in DMEMmedia
containing 10% FCS and G418 (250 μg/ml). Cells were maintained at 37°C, 5% CO2 in a
humid atmosphere. Cerebral cortices were dissected from either CD1 or PTENflox/flox E14.5
mouse embryos, dissociated in 0.33 mg/ml trypsin (Worthington, UK) in HBSS (Gibco, UK)
for 15 min at 37°C and gently triturated with a fire polished Pasteur pipette in Neurobasal
medium (Gibco, UK) supplemented with 2% fetal calf serum (FCS), 2% B27, 1% Glutamax and
1% penicillin/streptomycin (P/S). Neurons seeded at a density of 2000 cell/mm2 on poly-L-
lysine coated culture plates.
Immuofluoresence staining
U87MG cells stably expressing FKBP-PTEN were cultured on coverslips and fixed in 4% PFA
in PBS for 20 min. Cells were then washed with PBS and blocked in blocking buffer (0.5% Triton
X-100, 2% bovine serum albumin and 1% goat serum in PBS) for 1 h. Cells were incubated with
rabbit anti-PTEN for 1h at room temperature and washed 3 times in PBS, and incubated with
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an Alexa Fluor1 488 anti-Rabbit IgG, Alexa Fluor1 568 Phalloidin and Hoechst for 1 h at room
temperature. Cells were then washed three times in PBS and mounted using Mowiol1mount-
ing medium.
Transfection and nucleofection
Transfection of plasmid DNA into U87MG cells was carried out using GeneJuice (Novagen).
Nucleofection of mouse primary cortical neurons was performed by using Amaxa1Mouse
Neuron Nucleofector1 Kit (Lonza, UK). In order to monitor PTEN activity in transiently
transfected U87MG cells, the co-transfection of AKT-GFP with FKBP-PTEN or GFP-PTEN
constructs was exploited as a fast and effective experimental protocol that allowed the analysis
of PTEN activity towards PIP3-dependent signaling in transfected cell, only. This strategy was
pursued in transient transfections (Figs 1 and 2), but not in stable FKBP-PTEN expressing
U87MG cells lines (Fig 3).
Western blotting
U87MG cells or primary neuron cultures was washed with ice-cold PBS and then lysed in lyses
buffer (50 mM Tris-HCl, pH7.5, 150 mMNaCl; 1% Triton X-100; 500 μMNaF; 1 mM sodium
orthovanadate; 1X protease inhibitor) for 10 min. Cell debris was removed by centrifugation at
13000 rpm for 10 min. The boiled supernatants supplemented with SDS loading sample buffer
were loaded and run on 8% SDS-PAGE gel. Separated proteins were transferred to a nitrocellu-
lose membrane. Blots were blocked in 5% skimmed milk powder in TBST (20 mM Tris; 150
mMNaCl; 0.1% Tween) for 1 h and incubated with primary antibody in 5% skimmed milk
powder/TBST overnight at 4°C or for 1h at room temperature. The expression of proteins was
visualized by HRP-conjugated secondary antibody and enhanced Chemiluminescence Kit
(Pierce).
Colony formation assay
A single-cell suspension was prepared in 0.35% low melting point agar and plated (100 or 200
cells per well) in 24 well plates, which were pre-coated with 0.5% agar. Cell were then cultured
for 3 weeks in media containing different concentrations of Shld1. Experiments were analyzed
according to the protocol published by Franken et al. [11]. Plating efficiency was determined
by the ratio of the number of colonies to the number of cells seeded.
Cell invasion assay
Cell invasion assay was performed using BioCoat™ invasion chamber (BD Biosciences) with
8μm pore, according to the manufacturer’s instructions (BD Biosciences) with minor modifica-
tions. 0.5 ml of cell suspension (2.5x104 cells per well) prepared in serum-free media was added
on rehydrated 24-well BioCoat™Matrigel™ Invasion Chambers, which were placed in 24-well
plate containing normal culture media (DMEM plus 10% FBS), and incubated in a humidified
tissue culture incubator for 19 h, at 37°C, 5% CO2 atmosphere. The cells were fixed with 4%
PFA, permeabilized with 100% methanol for 20 min and stained with 0.05% crystal violet for
10 min. The cells and matrigel on the upper surface of the Matrigel Invasion Chambers were
removed by scrubbing with cotton buds. Invasive cells were counted under microscope in 10
fields for each treatment.
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Fig 1. Consequence of linker optimization on PTEN activity of the FKBP*-PTEN fusion protein. (A) Rationale of the DD-technology: Fusion of PTEN
with a modified human FKBP variant harboring the F36V and L106P point mutations (FKBP*) leads to degradation of the fusion protein. Presence of the
FKBP* ligand Shld1 confers stabilisation of FKBP*-PTEN and results in inhibition of PI3K/Akt signaling. (B) The fusion protein FKBP*-PTEN shows no
PTEN activity. PTEN-deficient U87MG cells were transiently co-transfected with FKBP*-PTEN and AKT-GFP. After one day, cells were treated with Shld1
for 12 hours at 1μM before cell lysis and samples analyses by western blotting using indicated antibodies. (C) Consequence of linker optimization on PTEN
activity of the FKBP*-PTEN fusion protein. Schematic representation of linker optimization. FKBP*-linker-PTEN variants with different linker regions (A-E)
were generated. Linker A—short flexible linker; Linker B—a helix forming linker. Linker C—long flexible linker. Linker D—long flexible linker containing the
PWRmotif. Linker E—the original linker present in the enzymatic active GFP-PTEN. (D) Analyses of the effect of different linkers on PTEN activity in FKBP*-
PTEN fusion variants in U87MG cells. Constructs expressing FKBP*-PTEN variants or GFP-PTEN were co-transfected with AKT-GFP into a PTEN null
U87MG cells. Stabilization of FKBP*-PTEN or GFP-PTEN in presence or absence of Shld1 was monitored by PTEN antibody. The phosphorylation level of
AKT-GFP at Ser473 served as a fast and effective experimental protocol to control for PTEN activity towards PIP3-dependent signaling in transfected cells,
only. Only constructs 4 and 5, which contain proline in the linker sequence, showed moderate PTEN activity towards PI3K signaling.
doi:10.1371/journal.pone.0145783.g001
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Zebrafish microinjection and visualization of FKBP**-PTEN expression
U87MG cells stably expressing FKBP-PTEN were transiently transfected with RFP or pre-
stained with DiI (Sigma). Approximately 100 cells were then microinjected into the perivitel-
line cavity of 2 dpf (day of post fertilization) zebrafish larvae. Fish larvae were immediately
imaged under an inverted fluorescence microscope (0 dpi) and then transferred into Danieau’s
solution containing 4 μM Shld1 or control media containing no Shld1. Fish larvae were again
imaged after 24h (1dpi) to analyze the effect of Shld1 induced FKBP-PTEN stabilization on
tumor growth and migration.
FKBP-PTEN stabilization in fish larvae was verified by immuostaining with PTEN anti-
body. Briefly, embryos were fixed in 4% PFA in PBS overnight at 4°C, and then sequentially
dehydrated with 15% and 30% sucrose. Cryosections were stained by immunofluorescence
staining protocols. Images were obtained by confocal microscopy.
Statistical analysis
The migration of the injected U87MG cells stably expressing FKBP-PTEN in fish embryos in
presence or absence of Shld1 were analysed in a similar way to fluorescent protein diffusion
profiles [12] using the Radial Profile Plot plug-in of ImageJ. The concentric movement of cells
away from a central point was quantified as a measure of increased fluorescence intensity at a
distance from the central point over time. Curve fitting was carried out in Excel using the
Fig 2. FKBP surface engineering restores PTEN activity of FKBP**-PTEN fusion protein. (A) Electrostatic potential map of PTEN (PDB ID: 1d5r) and
FKBP (PDB ID: 1BL4). Positively charged binding pocket of the PTEN PIP3 substrate is circled with a white dashed line; the negatively charged lump formed
by E31/D32 residues on the FKBP surface is circled by a black dashed line. (B) Schematic representation of amino acid residue substitutions of FKBP*
protein surface at E31/D32. (C) Different FKBP*-PTENmutants were transiently co-tansfected with AKT-GFP into U87MG cells, the expression of fusion
protein and pAKT were examined byWestern blotting. (D) E31S/D32S amino acid substitutions on FKBP* (FKBP**) restores PTEN activity of the FKBP**-
PTEN fusion protein. FKBP**-PTEN (or GFP/GFP-PTEN) was transiently co-expressed with AKT-GFP in U87MG cells. Cells were treated with Shld1 and
analyzed as before.
doi:10.1371/journal.pone.0145783.g002
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equation: f(t) = b0 exp(-b1)(t) where b0 and b1 are parameters of the curve. Migration index (Mi)
was calculated by as a ratio of b0 at time points 1dpi and 0dpi (Mi = b0(1dpi)/b0(0dpi)). The aver-
age migration index of control group (without Shld1 treatment, n = 13) is compared with that
of Shld1 treated group (n = 11). The size of tumor mass was measured by ImageJ. The average
ratio of tumour mass size (1 dpi/0 dpi) was calculated and analyzed by Excel1 and SPSS using
student two tailed t-test p<0.01;  p<0.001.
Results
We fused PTEN at the C-terminus of the FKBPF36V/L106P-based DD (FKBPF36V/L106P will be
referred to as FKBP) using a 12 aa linker sequence (-SSSSFEFALLPD-). We proposed that in
the absence of Shld1, FKBP would be rapidly degraded by the ubiquitin proteasome system
[13], resulting in the loss of FKBP-PTEN fusion protein, whereas addition of Shld1 will stabi-
lize the protein and inhibit PI3K/Akt signaling (Fig 1a). Although expression levels of the
FKBP-linker-PTEN fusion demonstrated Shld1 dependency, the protein did not alter PI3K/
Akt signaling (Fig 1b). FKBP has been successfully used to regulate a number of different
Fig 3. Engineered FKBP** permits rapid, reversible and tunable regulation of PTEN function in cellular models. (A) FKBP**-PTEN is reversibly
regulated in response to Shld1 treatment in cells. U87MG cells stably expressing FKBP**-PTEN were treated with vehicle or with Shld1 (1μM) for 24 h. One
set of cells was then washed thoroughly with DMEM and cultured in Shld1-free culture media for further 24hs. The expression level of FKBP**-PTEN was
examined by immunofluorescence staining. (B) upper panel, U87MG cells stably expressing FKBP**-PTEN were treated with Shld1 (1 μM) for different time
periods; lower panel, Shld1 (1 μM) was removed after 24 h treatment, and cultured in Shld1 free culture media for different time periods as indicated. (C)
PTEN protein levels and activity can be maintained at specific concentrations over a prolonged period of time in dependence of Shld1. U87MG cells stably
expressing FKBP**-PTEN were cultured in media containing indicated concentrations of Shld1 for 24 h. (D) Stable FKBP**-PTEN expressing U87MG cells
were analyzed in cell invasion (left) and colony formation (right) assays. In the cell invasion assay, data are shown as the mean ±SEM of the number of cells
migrated in three independent experiments. Plating efficiency refers to the ratio of the number of colonies to the number of cells seeded, shown as mean
±SEM of three independent experiments.
doi:10.1371/journal.pone.0145783.g003
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proteins, including cdc42 [14], RhoA [14], and MLYCD [15], with no reported interference in
their activity. We therefore surmised that the linker might not be suitable for generating biolog-
ical active FKBP-PTEN. Based on available knowledge regarding linker optimization [16,17],
we composed a number of different peptide sequences with the aim of restoring PTEN activity
in the FKBP-linker-PTEN fusion protein (Fig 1c). However, the most theoretically effective
linkers [17], a helix forming linker or a long flexible linker, did not restore PTEN activity as
verified by analyzing pAkt levels in PTEN-null U87MG glioblastoma cells transfected with
linker variants (Fig 1d). In contrast, a linker containing the unique cyclic imino acid proline,
which is unable to form hydrogen bonds to surrounding amino acids, was able to slightly
improve PTEN activity (linker sequence 4, Fig 1d). This limited success in restoring PTEN
activity using linker optimization suggest that other mechanisms impede biological function of
the phosphatase when presented in the FKBP-PTEN fusion protein.
FKBP surface engineering restores PTEN activity of the FKBP-PTEN
fusion protein
We considered the possibility that FKBP might directly interfere with PTEN activity by block-
ing substrate access to the active site of the enzyme, which consists of a large pocket with posi-
tive charges that accommodates the PTEN phosphoinositide substrates (Fig 2a). Indeed, the
electrostatic potential maps of the PTEN surface (PDB ID: 1d5r) and the FKBP surface (PDB
ID: 1BL4) revealed complementary charge distributions of the PTEN substrate binding region
and large negatively charged protrusions present on the FKBP surface (Fig 2a). Therefore, we
engineered the FKBP surface such that the charged regions were neutralized by replacing two
acidic amino acid residues (E31 and D32) with basic amino acid residues (Arg or Lys), with
polar uncharged residues (Ser), with hydrophobic residues (Val or Ala), or with the small
amino acid Gly (Fig 2b). Transfection of FKBP-PTEN surface engineered variants into
U87MG cells demonstrated that FKBP modifications containing the aa substitutions E31S/
D32S, E31G/D32G or E31A/D32A (Fig 2b, PTEN variants 4, 6, 7) resulted in Shld1 dependent
regulation of PTEN activity towards PI3K/Akt signaling. However, only the E31S/D32S FKBP
mutant was efficiently stabilized by Shld1 (Fig 2c). Hereafter, we refer to FKBPE31S/D32S-
PTEN as FKBP-PTEN. As the expression level of stabilized FKBP-PTEN defines the
dynamic range of the scalability of the FKBP-PTEN regulation system, we exploited the
strong CAG promoter sequence, a combination of the CMV early enhancer element and the
chicken beta-actin promoter to drive FKBP-PTEN expression. Subcloning of the FKBP-
PTEN cassette into a pCAG vector increased the level of protein expression and activity of
FKBP-PTEN to a level comparable to GFP-PTEN (Fig 2d).
Engineered FKBP** permits rapid, reversible and tunable regulation of
PTEN function in cellular and zebrafish models
To further characterize the scalability, speed and reversibility of FKBP-PTEN in response to
Shld1, we generated a U87MG cell line stably expressing FKBP-PTEN under the control of
the CAG promoter (Fig 3). Immunofluorescence labeling of these cells revealed that FKBP-
PTEN was robustly stabilized following the addition of Shld1, and this stabilization could be
abolished by Shld1 washout (Fig 3a and 3b). FKBP-PTEN protein levels were gradually up-
regulated with increasing Shld1 concentration, resulting in a concomitant decrease in phos-
phorylated Akt, indicating that PI3K signaling can be fine-tuned by altering the level of
FKBP-PTEN (Fig 3c). The time-dependent stabilization profile of FKBP-PTEN showed
that the engineered FKBP responded within a few hours of addition of Shld1 and reached a
plateau after 8 h (Fig 3b). Thus, the stabilization kinetics of FKBP is comparable to, or even
FKBP Protein Surface Engineering and Gene Codon-Optimization
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faster than that of FKBP [14]. We also discovered a rapid turnover of FKBP-PTEN within a
few hours after the removal of Shld1 (Fig 3b). The half-life of FKBP-PTEN fusion protein is
as short as 2-4h, which is comparable to FKBP [15] and to approximately 5% of the 48–72 h
half-life of endogenous PTEN [18]. Thus, our engineered FKBP provides an efficient molecu-
lar tool to manipulate PTEN activity in a scalable, rapid and reversible manner. To characterize
whether our engineered FKBP could finely tune PTEN activity and regulate biological
responses, we carried out in vitro invasion and colony formation assays [11,19] using the
FKBP-PTEN U87MG cell line. Cell invasion and colony formation in FKBP-PTEN
U87MG cells, but not wild type U87MG cells, could be inhibited by Shld1 in a dose-dependent
manner (Fig 3d). Thus, Shld1 can be used to fine tune PTEN activity to inhibit tumor growth
and tumor cell division.
To investigate whether Shld1 can induce FKBP-PTEN stabilization and control biological
responses in vivo, we used an established zebrafish metastasis model [20], and microinjected
the FKBP-PTEN U87MG cells, either pre-stained with DiI or transfected with RFP, into the
perivitelline cavity of 2 days post fertilization (dpf) zebrafish larvae. Larvae were then trans-
ferred into Danieau’s solution with or without 4μM Shld1. Images of larvae were taken imme-
diately after injections and 24h post-injection (Fig 4a). The migration indices and the increase
in tumor mass size of transplanted cells were quantified over this time-course. These experi-
ments demonstrated that Shld1 is effective in stabilizing FKBP-PTEN in zebrafish larvae,
resulting in inhibition of invasion and growth of FKBP-PTEN U87MG cells (Fig 4b). They
also show for the first time that DD-systems can be used effectively to manipulate protein levels
on demand in the zebrafish.
Codon optimization of FKBP** establishes a conditional fine-tuning
protein regulation system
In order to achieve advanced regulation of protein function, it would be desirable to combine
tunable FKBP-PTEN with established systems enabling precise control of gene expression,
such as the Cre/LoxP system (Fig 5a). For this purpose, FKBP-PTEN was subcloned immedi-
ately downstream of the second LoxP site of the LoxP-Stop-LoxP (LSL) cassette. We tested the
pCAG-LSL-FKBP-PTEN construct in mouse cortical neuronal primary cultures by transient
co-transfection with Cre-IresRFP (or, in control experiments, RFP). The FKBP-PTEN fusion
protein was only detectable by western blotting in the presence of Cre, and following applica-
tion of the synthetic ligand Shld1 (Fig 5b). Surprisingly, when Cre and FKBP-PTEN were co-
expressed, the anti-PTEN antibody also identified a distinct protein band with lower molecular
weight than full-length FKBP-PTEN, which was stable even in the absence of Shld1. We rea-
soned that this protein could represent a form of FKBP-PTEN with a truncation in the
FKBP domain which allows it to escape Shld1 regulation. A mechanism involving Cre-
dependent truncation of FKBP-PTEN suggests that these two regulation systems could be
incompatible. Due to the sequence similarity of FKBP and the engineered FKBP domain it
is likely that this might also be true of the parental DD system. We therefore investigated the
potential sites of Cre action within the DD domain.
Cre recombinase is an enzyme known to catalyze site specific recombination events between
two DNA recognition sites (LoxP sites) of 34 base pairs, which form a stem-loop-stem struc-
ture. We aligned the LoxP sequence with the human FKBP DNA sequence and found an
88.9% similarity between the loop region of LoxP and the sequence surrounding the third ATG
of the human FKBP gene (M3Lcta and LoxPrev) (Fig 5c). Consequentially, the third ATG
region (ATGCTA) of the human FKBP gene might be erroneously recognized as a Cre cleav-
age site, resulting in the formation of a FKBP gene truncation in which translation begins from
FKBP Protein Surface Engineering and Gene Codon-Optimization
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the fourth ATG. In this case, although the destabilizing site L106P on FKBP protein still
remains, the truncated FKBP might lose its destabilizing property as shown by the Shld1-in-
dependent band (Fig 5b). To test this idea, we replaced the high similarity region ATGCTA
(M3Lcta) of the human FKBP gene with silent mutations ATGTTG (M3Lttg). We found that
the truncated FKBP-PTEN band (Fig 5b) disappeared following mutations of Lcta to Lttg,
whilst the expression of full-length FKBP-PTEN remained both Cre- and Shld1-dependent
(Fig 5d). Thus, we engineered FKBP further to implement a functioning system that offers
dual control of FKBP-PTEN expression at transcription and posttranslational levels.
In order to test if PTEN loss can be directly coupled with the expression of tunable FKBP-
PTEN, we co-transfected M3Lttg pCAG-LSL-FKBP-PTEN with Cre-RFP (or RFP alone in
control experiments) into PTENflox/flox mouse neurons by nucleofection. Cre expression led to
substantial decreases in endogenous PTEN levels, and created Shld1 depended regulation of
exogenous FKBP-PTEN (Fig 5e). Thus, insertion of the LSL cassette ensures that loss of
endogenous PTEN and gain of tunable FKBP-PTEN takes place in the same cells.
Discussion
The targeting of protein stability with small molecules has emerged as a strategy in synthetic
biology to ascertain protein function. The technique involves genetically endowing the protein
Fig 4. Engineered FKBP** permits regulation of PTEN function in the zebrafish. (A) The migration and
growth of stable FKBP**-PTEN expressing U87MG cell clones injected into zebrafish embryos can be
inhibited by Shld1. Prior to microinjection into the perivitelline cavity of 2 days post fertilization (dpf) zebrafish
embryos, cells were pre-stained with DiI. Embryos were then transferred into fish water with (n = 11) or
without (n = 13) Shld1 (4 μM) and maintained for 24h. Images were taken immediately after injections (0 days
post injections, dpi) and after 24 h (1dpi). (B) The migration indices and the increase in tumor mass size of
transplanted cells were quantified. ** p<0.01; ***p<0.001.
doi:10.1371/journal.pone.0145783.g004
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of interest with a protein destabilizing domain specifically and reversibly controlled by a small
molecule, so that the stability of the fusion protein is dependent upon the sequence of the DDs
rather than that of the POI. An established DD sequence is based on a modified FKBP
(FKBPF36V/L106P); however, one of the recurring problems associated is the possible interfer-
ence of the FKBPF36V/L106P tag with electrostatic interactions, as well as the remaining unaf-
fected endogenous protein, which interfered here with the phosphatase activity of PTEN.
We modified FKBPF36V/L106P by neutralizing highly charged surface amino acid residues.
This modification resolved the problem of electrostatic interference by ensuring the full biolog-
ical activity of PTEN, which retains highly charged amino acids within the active site essential
for function. We demonstrate that our newly generated fusion protein (FKBP-PTEN) per-
mits rapid, reversible and tunable regulation of protein function in cellular as well as, for the
first time, in zebrafish models. Furthermore, we have rendered the system compatible with the
Cre-LoxP system. We identified and eliminated a potential Cre pseudo-cleavage site within the
FKBP gene. Following Cre-mediated recombination, expression of the FKBP-PTEN gene is
Fig 5. Codon optimization of FKBP** establishes a conditional fine-tuning protein regulation system. (A) The transcription of the destabilization
cassette FKBP**-PTEN was subcloned downstream of LoxP-Stop-LoxP; transcription was driven by the ubiquitous CMV-enhanced chicken beta actin
promoter (CAG). Presence of Cre induces FKBP**-PTEN gene transcription; however, the translated FKBP**-PTEN will be rapidly degraded. Addition of
Shld1 confers FKBP**-PTEN stabilization in a tunable and reversible manner. (B) Cre-mediated cleavage of LoxP-Stop-LoxP (LSL) created a truncated
FKBP**-PTEN fusion protein. Mouse forebrain neurons were nucleofected with LSL-FKBP**-PTEN and Cre-IresRFP (Cre (+)), or RFP (Cre (-)). Cells were
treated with Shld1 (or control vehicle) overnight, before analyses of cell lysates using indicated antibodies. (C) Sequence alignment of FKBP** and LoxP.
The third ATG codon region sequence (TATGCTA) of FKBP** (M3Lcta) is identical to the linker region of the LoxP stem-loop sequence (TATGCTA). Codon
optimization of CTA with TTG (both code for amino acid Leu) will destroy the potential pseudo-cleavage site of Cre on FKBP**. (D) Codon optimization of
M3Lcta to M3Lttg in FKBP** abolished the Cre-dependent FKBP**-PTEN truncation and produced a Shld1 dependent PTEN fusion protein. The M3Lttg
modified LSL-FKBP**-PTEN construct was co-expressed with Cre-IresRFP (Cre (+)), or RFP (Cre (-)) in mouse forebrain neurons as before. (E)
Combinatorial use of the Cre-LoxP system with the FKBP**-PTEN/Shld1 chemical-genetic protein control system in PTENflox/flox cells. Constructs were
nucleofected into PTENloxp/loxpmouse primary neurons as before. Note that nucleofection of primary cells occurs with efficiencies at approx. 80%, and result
in a residual endogenous PTEN signals detected by western blotting. (F) The generated system is able to couple PTEN-loss directly with the expression of
tunable FKBP**-PTEN. Upon Cre-mediated recombination, PTENloxp/loxp cells will lose PTEN and, at the same time, activate expression of FKBP**-PTEN.
In essence, endogenous PTEN is replaced by tuneable PTEN, which will enable to test whether PTEN-loss induced phenotypes can be rescued at different
time-points (tShld1) and/or at different PTEN-concentrations (dShld1).
doi:10.1371/journal.pone.0145783.g005
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achieved. The system now provides two layers of control over protein levels and activity: the
first operating at transcriptional and the second at posttranslational level.
The development of the FKBP-Shield1/Cre-LoxP system offers unique possibilities to
manipulate protein function in vitro and in vivo, by combining the loss of endogenous proteins
directly with the expression of tunable versions. This system is compatible with the building of
sophisticated protein regulation networks as FKBP-tagged proteins, as well as conditional
mouse alleles can be selected and combined as required. Additionally, the system allows precise
and effortless control over the re-installment of protein function following molecular deficits,
thus offering a powerful means with which to address the reversibility of a number disease
states, in particular those associated with developmental disorders. Therefore, this study con-
solidates and extends the use of DD-technology to manipulate protein function in a specific,
fast, reversible and tunable manner.
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